Company: NCL
Filing Date: 2025-09-26
Form Type: S-1
Source: 0001575872-25-000602
Chunk: 60

Company: Northann Corp.
Filing Date: 2025-09-26
Form: S-1
Chunk 60
---
 the company engaged an auditor that has not been subject to an
inspection by the PCAOB, an auditor that PCAOB cannot inspect, or an auditor that has not demonstrated sufficient resources, geographic
reach, or experience to adequately perform the company’s audit. Our public offering will be relatively small and the insiders of
our Company will hold a large portion of the company’s listed securities. NYSE American might apply additional and more stringent
criteria for our initial and continued listing, which might cause a delay or even denial of our listing application.

| 25 |

Anti-takeover provisions in our charter documents and Nevada law could discourage, delay or prevent a change in control of our company and may affect the trading price of our common stock.

We are a Nevada corporation and the anti-takeover provisions
of the Nevada Revised Statutes may have the effect of deterring unsolicited takeovers or delaying or preventing a change in
control of our company or changes in our management, including transactions in which our stockholders might otherwise receive a premium
for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions
that they may deem to be in their best interests. These provisions include:

| · | the inability of stockholders holding less than a majority of the voting 
 shares outstanding to call special meetings;                             |

| · | the “business combinations” and “control share acquisitions” provisions of Nevada                                                           
 law, to the extent applicable, could discourage attempts to acquire our stockholders stock even on terms above the prevailing market price; 
 and                                                                                                                                         |

| · | the ability of our board of directors to designate the terms of and issue new series of preferred stock                                
 without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used  
 to institute a rights plan, also known as a poison pill, that would dilute the stock ownership of a potential hostile acquirer, likely 
 preventing acquisitions that have not been approved by our board of directors.                                                         |

The existence of the forgoing
provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common
stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for
your common stock in an acquisition.

In addition, our Articles of Incorporation and Bylaws
may discourage, delay, or prevent a change in our management or control over us